Hubbry Logo
MRI contrast agentMRI contrast agentMain
Open search
MRI contrast agent
Community hub
MRI contrast agent
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
MRI contrast agent
MRI contrast agent
MRI contrast agent
View on Wikipedia
from Wikipedia

Real-time MRI of a child swallowing pineapple juice whose naturally high content in paramagnetic manganese allows it to be used as an MRI contrast agent

MRI contrast agents are contrast agents used to improve the visibility of internal body structures in magnetic resonance imaging (MRI).[1] The most commonly used compounds for contrast enhancement are gadolinium-based contrast agents (GBCAs). Such MRI contrast agents shorten the relaxation times of nuclei within body tissues following oral or intravenous administration. Due to safety concerns, these products carry a Black Box Warning in the US.

Theory of operation

[edit]

In MRI scanners, sections of the body are exposed to a strong magnetic field causing primarily the hydrogen nuclei ("spins") of water in tissues to be polarized in the direction of the magnetic field. An intense radiofrequency pulse is applied that tips the magnetization generated by the hydrogen nuclei in the direction of the receiver coil where the spin polarization can be detected. Random molecular rotational oscillations matching the resonance frequency of the nuclear spins provide the "relaxation" mechanisms that bring the net magnetization back to its equilibrium position in alignment with the applied magnetic field. The magnitude of the spin polarization detected by the receiver is used to form the MR image but decays with a characteristic time constant known as the T1 relaxation time. Water protons in different tissues have different T1 values, which is one of the main sources of contrast in MR images. A contrast agent usually shortens, but in some instances increases, the value of T1 of nearby water protons thereby altering the contrast in the image.

Most clinically used MRI contrast agents work by shortening the T1 relaxation time of protons inside tissues via interactions with the nearby contrast agent. Thermally driven motion of the strongly paramagnetic metal ions in the contrast agent generate the oscillating magnetic fields that provide the relaxation mechanisms that enhance the rate of decay of the induced polarization. The systematic sampling of this polarization over the spatial region of the tissue being examined forms the basis for construction of the image.

MRI contrast agents may be administered by injection into the blood stream or orally, depending on the subject of interest. Oral administration is well suited to gastrointestinal tract scans, while intravascular administration proves more useful for most other scans.

MRI contrast agents can be classified[2] by their:

  • Chemical composition
  • Administration route
  • Magnetic properties
  • Biodistribution and applications:
    • Extracellular fluid agents (intravenous contrast agents)
    • Blood pool agents (intravascular contrast agents)
    • Organ specific agents (gastrointestinal contrast agents and hepatobiliary contrast agents)
    • Active targeting/cell labeling agents (tumor-specific agents)
    • Responsive (smart or bioactivated) agents
    • pH-sensitive agents

Gadolinium(III)

[edit]
Effect of contrast agent on images: Defect of the blood–brain barrier after stroke shown in MRI. T1-weighted images, left image without, right image with contrast medium administration.

Gadolinium(III) containing MRI contrast agents (often termed simply "gado" or "gad") are the most commonly used for enhancement of vessels in MR angiography or for brain tumor enhancement associated with the degradation of the blood–brain barrier (BBB).[3][4] Over 450 million doses have been administered worldwide from 1988 to 2017.[5] For large vessels such as the aorta and its branches, the dose can be as low as 0.1 mmol/kg of body mass. Higher concentrations are often used for finer vasculature.[6] At much higher concentration, there is more T2 shortening effect of gadolinium, causing gadolinium brightness to be less than surrounding body tissues.[7] However at such concentration, it will cause greater toxicity to bodily tissues.[8]

Gd3+ chelates are hydrophilic and do not readily cross the intact blood–brain barrier. Thus, they are useful in enhancing lesions and tumors where the blood–brain barrier is compromised and the Gd(III) leaks out.[9][a] In the rest of the body, the Gd3+ initially remains in the circulation but then distributes into the interstitial space or is eliminated by the kidneys.

Available gadolinium-based contrast agents (GBCAs) (brand names, approved for human use by EMA[10][when?] and by the FDA in 1988;[11][12] (standard dose[13])):

Extracellular fluid agents

[edit]

Blood pool agents

[edit]

Hepatobiliary (liver) agents

[edit]
  • gadoxetic acid (Primovist [EU] / Eovist [US]) is used as a hepatobiliary agent as 50% is taken up and excreted by the liver and 50% by the kidneys.

Safety

[edit]
Main article: Nephrogenic systemic fibrosis

The use of Gd3+ chelates in persons with acute or chronic kidney disease can cause nephrogenic systemic fibrosis (NSF),[17][18][19] a rare but severe systemic disease resembling scleromyxedema and to some extent scleroderma. It may occur months after contrast injection.[20] Patients with severely deteriorated kidney function are more at risk for NSF, with dialysis patients being more at risk than patients with mild chronic kidney disease.[21][22] NSF can be caused by linear and macrocyclic gadolinium-containing MRI contrast agents,[23][24] although macrocyclic ionic compounds have been found the least likely to release the Gd3+.[25][17]

While NSF is a severe form of disease, gadolinium deposition disease (GDD) is a mild variant with pain (e.g. headache), fatigue, and / or gadolinium depositions.[26]

As a free solubilized aqueous ion, gadolinium(III) is highly toxic, but the chelated compounds are relatively safe for individuals without kidney disease. Free Gd3+ has a median lethal dose of 0.34 mmol/kg (IV, mouse)[27] or 100–200 mg/kg, but the LD50 is increased by a factor of 31 times[28] when Gd3+ is chelated.[29]

The spectrum of adverse drug reactions is greater with gadolinium-based contrast agents than with iodinated contrast agents (radiocontrast agents).[30]

Gadolinium has been found to remain in the brain, heart muscle, kidney, liver, and other organs after one or more injections of a linear or macrocyclic gadolinium-based contrast agents, even after a prolonged period of time.[31][32] The amount differs with the presence of kidney injury at the moment of injection, the molecular geometry of the ligand, and the dose administered.[citation needed]

In vitro studies have found gadolinium-based contrast agents to be neurotoxic,[33] and a study found signal intensity in the dentate nucleus of MRI (indicative of gadolinium deposition) to be correlated with lower verbal fluency.[34] Confusion is often reported as a possible clinical symptom.[33] The FDA has asked doctors to limit the use of gadolinium contrast agents to examinations where necessary information is obtained only through its use.[35] Intrathecal injections of doses higher than 1 mmol are associated with severe neurological complications and can lead to death.[36][37] The glymphatic system could be the main access of GBCA to the brain in intravenous injection.[38][39]

Continuing evidence of the retention of gadolinium in brain and other tissues following exposure to gadolinium containing contrast media, led to a safety review by the Committee for Medicinal Products for Human Use (CHMP) which led the EMA to restrict or suspend authorization for the intravenous use of most brands of linear gadolinium-based media, in which Gd3+ has a lower binding affinity, in 2017.[16][40]

In the United States, the research has led the FDA to revise its class warnings for gadolinium-based contrast media. It is advised that the use of gadolinium-based media should be based on careful consideration of the retention characteristics of the contrast, with extra care being taken in patients requiring multiple lifetime doses, pregnant, and paediatric patients, and patients with inflammatory conditions. They also advise minimizing repeated GBCA imaging studies when possible, particularly closely spaced MRI studies, but not avoiding or deferring necessary GBCA MRI scans.[41]

In December 2017, the FDA announced that it was requiring these warnings to be included on all GBCAs. The FDA also called for increased patient education and requiring gadolinium contrast vendors to conduct additional animal and clinical studies to assess the safety of these agents.[42]

The French health authority recommends to use the lowest possible dose of a GBCA and only when essential diagnostic information cannot be obtained without it.[43]

The World Health Organization issued a restriction on use of several gadolinium contrast agents in November 2009 stating that "High-risk gadolinium-containing contrast agents (Optimark, Omniscan, Magnevist, Magnegita, and Gado-MRT ratiopharm) are contraindicated in patients with severe kidney problems, in patients who are scheduled for or have recently received a liver transplant, and in newborn babies up to four weeks of age."[44]

In magnetic resonance imaging in pregnancy, gadolinium contrast agents in the first trimester is associated with a slightly increased risk of a childhood diagnosis of several forms of rheumatism, inflammatory disorders, or infiltrative skin conditions, according to a retrospective study including 397 infants prenatally exposed to gadolinium contrast.[45] In the second and third trimester, gadolinium contrast is associated with a slightly increased risk of stillbirth or neonatal death, by the same study.[45]

Guidelines from the Canadian Association of Radiologists[46] are that dialysis patients should receive gadolinium agents only where essential and that they should receive dialysis after the exam. If a contrast-enhanced MRI must be performed on a dialysis patient, it is recommended that certain high-risk contrast agents be avoided but not that a lower dose be considered.[46] The American College of Radiology recommends that contrast-enhanced MRI examinations be performed as closely before dialysis as possible as a precautionary measure, although this has not been proven to reduce the likelihood of developing NSF.[47] The FDA recommends that potential for gadolinium retention be considered when choosing the type of GBCA used in patients requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions.[48]

Anaphylactoid reactions are rare, occurring in about 0.03–0.1%.[49]

Iron oxide: superparamagnetic

[edit]
Main article: Superparamagnetic relaxometry

Two types of iron oxide contrast agents exist: superparamagnetic iron oxide (SPIO) and ultrasmall superparamagnetic iron oxide (USPIO). These contrast agents consist of suspended colloids of iron oxide nanoparticles and when injected during imaging reduce the T2 signals of absorbing tissues. SPIO and USPIO contrast agents have been used successfully in some instances for liver lesion evaluation.[50][51]

  • Feridex I.V. (also known as Endorem and ferumoxides). This product was discontinued by AMAG Pharma in November 2008.[52]
  • Resovist (also known as Cliavist). This was approved for the European market in 2001, but production was abandoned in 2009.[53]
  • Sinerem (also known as Combidex). Guerbet withdrew the marketing authorization application for this product in 2007.[54]
  • Lumirem (also known as Gastromark). Gastromark was approved by the FDA in 1996[55] and was discontinued by its manufacturer in 2012.[56][57]
  • Clariscan (also known as PEG-fero, Feruglose, and NC100150). This iron based contrast agent was never commercially launched and its development was discontinued in early 2000s due to safety concerns.[58] In 2017 GE Healthcare launched a macrocyclic extracellular gadolinium based contrast agent containing gadoteric acid as gadoterate meglumine under the trade name Clariscan.[59]

Iron platinum: superparamagnetic

[edit]

Superparamagnetic iron–platinum particles (SIPPs) have been reported and had significantly better T2 relaxivities compared with the more common iron oxide nanoparticles. SIPPs were also encapsulated with phospholipids to create multifunctional SIPP stealth immunomicelles that specifically targeted human prostate cancer cells.[60] These are, however, investigational agents which have not yet been tried in humans. In a recent study, multifunctional SIPP micelles were synthesized and conjugated to a monoclonal antibody against prostate-specific membrane antigen.[60] The complex specifically targeted human prostate cancer cells in vitro, and these results suggest that SIPPs may have a role in the future as tumor-specific contrast agents.[citation needed]

Manganese

[edit]

Manganese(II) chelates such as Mn-DPDP (mangafodipir) enhance the T1 signal.[61] The chelate dissociates in vivo into manganese and DPDP; the manganese is excreted in bile, while DPDP is eliminated via kidney filtration.[62] Mangafodipir has been used in human neuroimaging clinical trials, including for neurodegenerative diseases such as multiple sclerosis.[63][64] Manganese(II) ions are often used as a contrast agent in animal studies, often called MEMRI (manganese-enhanced MRI).[65] Because Mn2+ ions can enter cells through calcium transport channels, it has been used for functional brain imaging.[66]

Manganese(III) chelates with porphyrins and phthalocyanines have also been studied.[61]

Unlike the other well-studied iron oxide-based nanoparticles, research on Mn-based nanoparticles is at a relatively early stage.[67]

Oral administration

[edit]

A wide variety of oral contrast agents can enhance images of the gastrointestinal tract. They include gadolinium and manganese chelates, or iron salts for T1 signal enhancement. SPIO, barium sulfate, air and clay have been used to lower T2 signal. Natural products with high manganese concentration such as blueberry and green tea can also be used for T1 increasing contrast enhancement.[68]

Perflubron, a type of perfluorocarbon, has been used as a gastrointestinal MRI contrast agent for pediatric imaging.[69] This contrast agent works by reducing the number of hydrogen ions in a body cavity, thus causing it to appear dark in the images.

Protein-based MRI contrast agents

[edit]
See also: Enzyme-activated MR contrast agents

Newer research suggests the possibility of protein based contrast agents, based on the abilities of some amino acids to bind with gadolinium.

See also

[edit]

Footnotes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

MRI contrast agent

View on Grokipedia
from Grokipedia
MRI contrast agents are pharmaceuticals administered intravenously to patients undergoing (MRI) to improve the diagnostic quality of images by altering the relaxation times of water protons in tissues, thereby enhancing the visibility of blood vessels, organs, tumors, and other structures. The most widely used type consists of gadolinium-based contrast agents (GBCAs), which primarily shorten the T1 relaxation time to produce brighter signals on T1-weighted MRI scans where the agent accumulates. These agents function as catalysts for water proton relaxation, with their effectiveness measured by relaxivity, and are typically dosed at 0.1 mmol/kg of body weight. GBCAs, the predominant class since their introduction, are chelated complexes of the paramagnetic (Gd³⁺) with ligands that prevent by stabilizing the and facilitating renal . Chemically, they are classified into macrocyclic and linear structures, with further subdivision into ionic and nonionic based on the chelating ligand's design, which influences stability and the risk of gadolinium release. Macrocyclic agents, such as gadoterate meglumine, offer higher stability and lower dissociation rates compared to linear ones like gadodiamide. Beyond GBCAs, other agents include manganese-based compounds and emerging responsive or targeted types for specific applications like . Recent approvals include gadopiclenol (2022), a macrocyclic agent with higher relaxivity enabling reduced doses. The development of MRI contrast agents began in the , with the first GBCA, gadopentetate dimeglumine (Magnevist®), approved for clinical use in 1988 following initial human trials in 1983. While nine GBCAs had been approved worldwide by 2017, some linear agents have since been withdrawn or restricted in certain regions due to safety concerns. As of 2023, more than 800 million GBCA doses have been administered worldwide, with approximately 63 million annually. Applications span imaging for tumors and , vascular assessments via MR angiography, hepatic lesion detection, and whole-body evaluations for and . Safety considerations are paramount, as free is highly toxic, potentially causing (NSF) in patients with severe renal impairment, though this risk has diminished with the use of more stable macrocyclic agents and screening protocols. Allergic-like reactions occur rarely, at rates lower than those for iodinated CT contrast agents, and GBCAs contain no iodine, making them suitable for iodine-allergic patients. Recent concerns include gadolinium retention in the brain and other tissues after repeated administrations, prompting regulatory updates and research into safer alternatives. Contraindications include , and use in is generally avoided unless benefits outweigh risks.

Fundamentals

Principles of Operation

(MRI) relies on the alignment of protons, primarily from molecules, in a strong external , denoted as B0. When a radiofrequency (RF) pulse is applied at the Larmor frequency, these protons absorb energy and deviate from alignment, creating a net . Upon cessation of the RF pulse, the protons relax back to equilibrium through two primary processes: T1 (longitudinal) relaxation, where recovers along the B0 direction, and T2 (transverse) relaxation, where decays in the plane perpendicular to B0 due to spin-spin interactions. These relaxation times determine the signal intensity in MRI images, with tissues exhibiting different T1 and T2 values producing inherent contrast; however, unenhanced MRI often lacks sufficient differentiation for certain pathologies. Contrast agents enhance this intrinsic contrast by accelerating T1 and/or T2 relaxation rates of nearby water protons, thereby altering signal intensity in regions of agent accumulation. Paramagnetic agents, such as those containing ions with unpaired electrons, generate local inhomogeneities that increase the fluctuating fields experienced by protons, shortening T1 relaxation and producing a brighter (T1-weighted) signal. Superparamagnetic agents, typically nanoparticles, induce stronger local field perturbations due to their large magnetic moments, predominantly shortening T2 relaxation and causing signal voids (darkening) in T2-weighted images. These perturbations arise from the agents' ability to create microscopic magnetic gradients, proton spins and modulating relaxation without requiring direct chemical binding to . Biologically, most MRI contrast agents are administered intravenously and distribute rapidly into the bloodstream before extravasating into the of tissues with permeable vasculature, such as tumors or inflamed areas, due to their small molecular size (typically <1 nm for gadolinium chelates). This distribution allows agents to highlight regions of abnormal vascular permeability or increased extracellular volume, improving visualization of lesions. Certain agents are designed to remain intravascular, bound to plasma proteins or as larger nanoparticles, to delineate vascular structures without leaking into tissues. The introduction of MRI contrast agents in the 1980s addressed the limitations of unenhanced imaging by providing dynamic enhancement patterns that reveal physiological processes like perfusion and leakage. The first paramagnetic agent, gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA), was tested in humans in 1983 and approved in 1988, marking a pivotal advancement in clinical MRI.

Relaxivity and Contrast Mechanisms

Relaxivity quantifies the ability of a contrast agent to enhance MRI signal by accelerating the relaxation of water protons, defined as the change in the longitudinal relaxation rate R1=1/T1R_1 = 1/T_1 per millimolar concentration of the agent for r1r_1, and similarly for the transverse relaxation rate R2=1/T2R_2 = 1/T_2 yielding r2r_2, with units of mM⁻¹ s⁻¹. These parameters describe the efficacy of paramagnetic or superparamagnetic agents in modulating T1- or T2-weighted images, where higher r1r_1 values promote brighter contrast in T1 imaging, while elevated r2r_2 enhances darkening in T2 imaging. The longitudinal and transverse relaxation rates in the presence of a contrast agent follow the linear relationships: 1T1=1T10+r1[CA]\frac{1}{T_1} = \frac{1}{T_1^0} + r_1 [\mathrm{CA}] 1T2=1T20+r2[CA]\frac{1}{T_2} = \frac{1}{T_2^0} + r_2 [\mathrm{CA}] where T10T_1^0 and T20T_2^0 are the intrinsic relaxation times of water without the agent, and [CA][\mathrm{CA}] is the agent concentration. Several factors influence relaxivity values, including magnetic field strength, where r1r_1 typically decreases at higher fields due to reduced proton-electron dipolar interactions, while r2r_2 may increase owing to enhanced susceptibility effects. Water exchange rates between coordinated and bulk water molecules are critical, as optimal rates (around 10⁸–10⁹ s⁻¹ at clinical fields) maximize inner-sphere contributions to r1r_1 by ensuring efficient proton relaxation without diffusional limitations. Other influences include the agent's rotational correlation time, which lengthens with molecular size or protein binding to boost relaxivity at low fields, and the number of inner-sphere water molecules, typically q=1–2 for gadolinium agents achieving high r1r_1. For paramagnetic agents, relaxation mechanisms are divided into inner-sphere, involving direct coordination of water protons to the metal ion followed by rapid exchange, and outer-sphere, arising from diffusional encounters with the agent's magnetic field without coordination. Inner-sphere relaxation dominates r1r_1 enhancement through dipole-dipole interactions modulated by electron spin relaxation and water residency times, while outer-sphere contributes more to r2r_2 via transient field perturbations. In superparamagnetic particles, such as iron oxides, contrast arises primarily from susceptibility effects, where the particles' large magnetic moments induce local field gradients that dephase nearby protons, strongly enhancing r2r_2 and r2∗r_2^* through static and motional averaging mechanisms. Relaxivity is measured using nuclear magnetic relaxation dispersion (NMRD) profiles, which plot r1r_1 or r2r_2 against magnetic field strength (or proton Larmor frequency, typically 0.01–100 MHz corresponding to 0.0002–2.35 T) to reveal field-dependent behaviors and predict in vivo performance. These profiles are obtained via field-cycling NMR relaxometry, fitting data to Solomon-Bloembergen-Morgan (SBM) theory for paramagnetic agents or extensions for nanoparticles, allowing extraction of key parameters like water exchange rates and rotational times. NMRD analysis is essential for optimizing agents, as it highlights dispersion peaks (e.g., around 20–40 MHz) linked to optimal relaxivity at clinical fields (1.5–3 T, ~64–128 MHz).

Gadolinium-Based Agents

Extracellular Fluid Agents

Extracellular fluid agents are gadolinium-based contrast agents (GBCAs) designed to distribute rapidly throughout the extracellular space, excluding the intracellular compartment, and are primarily excreted via the kidneys. These agents enhance MRI signal by shortening T1 relaxation times in tissues where they accumulate, particularly in areas with disrupted blood-brain barriers or increased vascular permeability. The first extracellular fluid agent, gadopentetate dimeglumine (Magnevist), was approved by the U.S. Food and Drug Administration in 1988 for use in MRI of the central nervous system. Since then, over 750 million doses of GBCAs, including these agents, have been administered worldwide. Key examples include linear chelates such as gadopentetate dimeglumine (Magnevist) and gadodiamide (Omniscan), which use open-chain ligands to bind gadolinium, and the macrocyclic chelate gadoteridol (ProHance), which employs a rigid cage-like structure for greater stability. Pharmacokinetically, these agents exhibit rapid distribution to the extracellular fluid following intravenous administration, with a distribution half-life of approximately 4 minutes and an elimination half-life of 1-2 hours in patients with normal renal function. They are administered at a standard dose of 0.1 mmol/kg body weight, primarily for renal clearance unchanged. In clinical practice, extracellular fluid agents are used to enhance the visibility of tumors, inflammatory processes, and lesions in brain, spine, and body imaging, aiding in the detection and characterization of pathologies such as multiple sclerosis plaques, metastases, and abscesses. For instance, they improve contrast in T1-weighted images for evaluating central nervous system tumors and inflammatory conditions. Although generally safe, linear agents like Omniscan carry a higher risk of nephrogenic systemic fibrosis in patients with severe renal impairment.

Blood Pool Agents

Blood pool agents represent a specialized class of gadolinium-based contrast agents engineered for extended retention within the vascular compartment, enhancing the visualization of blood vessels during magnetic resonance imaging (MRI). Unlike standard extracellular agents that rapidly distribute into interstitial spaces, these agents are formulated to minimize extravasation, enabling prolonged intravascular contrast and steady-state imaging. The prototypical example is gadofosveset trisodium (Ablavar, formerly Vasovist), a linear ionic gadolinium chelate featuring a diphenylcyclohexyl moiety that enables reversible, non-covalent binding to serum albumin. This binding restricts the agent to the bloodstream, significantly prolongs its circulation half-life to approximately 18.5 hours, and boosts its T1 relaxivity to about 19 L/mmol/s at 1.5 T—far higher than the 4-5 L/mmol/s typical of unbound gadolinium chelates—allowing for lower doses (0.03 mmol/kg) while achieving strong signal enhancement. Gadofosveset was approved by the FDA in 2008 specifically for magnetic resonance angiography (MRA) of the aortoiliac vasculature in adults with known or suspected peripheral vascular disease, but its commercial production was discontinued in 2017 due to market factors rather than safety concerns. High-concentration formulations of other gadolinium agents, such as gadobutrol (Gadavist), have been employed in vascular imaging protocols to mimic some blood pool characteristics; at 1.0 M concentration, gadobutrol delivers a compact bolus that enhances first-pass arterial signal and supports extended acquisition windows for MRA, though it eventually extravasates like conventional extracellular agents. These formulations leverage macromolecular interactions or optimized pharmacokinetics to extend effective circulation times to 2-4 hours, facilitating high-resolution imaging without the need for precise bolus timing. Clinically, blood pool agents like gadofosveset excel in MR angiography of both arteries and veins, providing robust depiction of peripheral, abdominal, and thoracic vasculature with reduced motion artifacts and higher spatial resolution. In cardiology, they support myocardial perfusion imaging and coronary MRA, enabling assessment of coronary artery disease and venous outflow syndromes. For oncology, these agents aid in perfusion studies to evaluate tumor vascularity and response to anti-angiogenic therapies, as well as imaging vascular malformations. Compared to extracellular agents, blood pool formulations offer superior vessel-to-background contrast, a wider imaging time window for complex protocols, and the potential for dose reduction, thereby improving diagnostic confidence in dynamic vascular assessments.

Hepatobiliary Agents

Hepatobiliary agents represent a subclass of gadolinium-based MRI contrast agents that exhibit dual elimination pathways, enabling both extracellular vascular enhancement and hepatocyte-specific uptake for targeted liver imaging. These agents are particularly valuable for distinguishing hepatocellular from non-hepatocellular lesions by leveraging the liver's functional transport mechanisms. The two primary examples in clinical use are (also known as gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid, marketed as Eovist in the United States and Primovist elsewhere) and gadobenate dimeglumine (Gd-BOPTA, marketed as MultiHance). Gadoxetic acid is taken up by functioning hepatocytes primarily through organic anion transporting polypeptide (OATP) transporters, such as OATP1B1 and OATP1B3, followed by excretion into bile via multidrug resistance-associated protein 2 (MRP2). Approximately 50% of the injected dose undergoes biliary elimination, with the remainder cleared renally, resulting in dual enhancement phases: an initial vascular phase similar to extracellular agents and a hepatobiliary phase that peaks 10-20 minutes post-injection. This agent was approved by the U.S. Food and Drug Administration in 2008 for intravenous use in adults to detect and characterize lesions in the liver. In clinical practice, gadoxetic acid enhances the detection of hepatocellular carcinoma (HCC) and small hepatic metastases, with studies showing improved sensitivity for lesions under 1 cm compared to extracellular agents alone, particularly through hypointense appearance on hepatobiliary phase imaging. It also aids in characterizing focal liver nodules by assessing hepatocyte function, where lesions lacking OATP expression appear dark against enhanced parenchyma. Delayed hepatobiliary imaging at 10-20 minutes post-injection is standard for optimal contrast. Gadobenate dimeglumine similarly undergoes partial hepatocyte uptake via OATP transporters but with lower hepatobiliary specificity, as only 3-5% of the dose is excreted biliarly, while the majority follows renal clearance. This results in prolonged extracellular enhancement combined with a weaker hepatobiliary phase, typically imaged 60-120 minutes post-injection to visualize biliary structures and assess liver function. Approved by the U.S. Food and Drug Administration in 2004, it supports liver lesion detection and characterization, including HCC and metastases, though its hepatobiliary contribution is less pronounced than that of .

Recent Developments

In recent years, significant advancements in gadolinium-based MRI contrast agents have focused on developing macrocyclic structures with enhanced relaxivity to improve safety and efficacy. Gadopiclenol (Vueway), approved by the FDA in September 2022, is a macrocyclic agent featuring a high r1 relaxivity of 18 mM⁻¹ s⁻¹ at 1T, enabling superior T1 shortening compared to traditional extracellular agents. Similarly, gadoquatrane, an investigational tetrameric macrocyclic agent, has demonstrated a high r1 relaxivity of 11.8 mM⁻¹ s⁻¹ per Gd at 1.41 T in preclinical studies, positioning it as a promising candidate with comparable performance. As of August 2025, Bayer's New Drug Application for gadoquatrane has been accepted by the U.S. FDA for review. These agents represent a shift toward higher-efficiency formulations that maintain diagnostic quality while addressing concerns over gadolinium retention. Key innovations in these agents include substantial reductions in gadolinium dosing and enhanced thermodynamic stability to minimize free Gd³⁺ dissociation. Gadopiclenol allows for a halved dose of 0.05 mmol/kg compared to standard 0.1 mmol/kg for legacy agents like gadobutrol, achieving equivalent or superior contrast enhancement due to its elevated relaxivity. Gadoquatrane further advances this by enabling a 60% dose reduction to 0.04 mmol/kg, with its multimeric design contributing to improved stability and reduced risk of dissociation, as evidenced in Phase III trials. These developments prioritize patient safety by lowering cumulative gadolinium exposure without compromising image quality. Post-approval clinical evaluations, including Phase IV studies, have confirmed gadopiclenol's efficacy in central nervous system (CNS) and body imaging. For instance, multicenter trials demonstrated noninferior lesion visualization and greater contrast enhancement in CNS MRI at the reduced dose, with gadopiclenol becoming commercially available in the US starting in 2023. Ongoing Phase IV assessments, such as those comparing it to gadobutrol for pituitary and brain lesion detection, continue to support its safety profile after the first year of use, reporting low adverse event rates. Regulatory bodies have reinforced the preference for macrocyclic agents following warnings on nephrogenic systemic fibrosis (NSF) associated with less stable linear agents. The FDA and EMA have updated guidelines emphasizing the use of macrocyclics like gadopiclenol and, pending approval, gadoquatrane, due to their superior stability and negligible NSF risk, even in patients with renal impairment. These updates, building on 2017 FDA communications, aim to minimize gadolinium-related risks while facilitating broader clinical adoption of next-generation agents.

Superparamagnetic Agents

Iron Oxide Agents

Iron oxide agents, primarily superparamagnetic iron oxide nanoparticles (SPIONs), serve as negative contrast agents in MRI by shortening T2 and T2* relaxation times, producing areas of signal void or darkening on images. These particles exhibit superparamagnetism, where their magnetic moments align strongly with an external field but relax rapidly without remanence due to thermal agitation. SPIONs are classified into superparamagnetic iron oxide (SPIO) particles, typically 50-150 nm in diameter, and ultrasmall superparamagnetic iron oxide (USPIO) particles, ranging from 5-50 nm. Representative SPIO formulations include ferumoxides (Feridex in the US and Endorem in Europe), which consist of magnetite cores coated with dextran for stability and biocompatibility. USPIO examples include ferumoxytol, a carboxymaltose-coated iron oxide nanoparticle originally approved as Feraheme for iron supplementation in patients with anemia and, as of October 2025, approved by the FDA as Ferabright for use as an MRI contrast agent in adults with known or suspected malignant brain neoplasms. Another SPIO, ferucarbotran (Resovist), featured a carboxydextran coating but was discontinued. These agents feature a core-shell structure, with an iron oxide core (often magnetite or maghemite) encapsulated in hydrophilic coatings like dextran to prevent aggregation and enable intravenous administration. Particle sizes influence biodistribution and relaxivity; larger SPIO particles are rapidly cleared by the reticuloendothelial system, while smaller USPIOs exhibit prolonged blood circulation. They demonstrate high transverse relaxivity (r2) relative to longitudinal relaxivity (r1), with r2/r1 ratios often exceeding 10, enhancing T2-weighted contrast through magnetic susceptibility effects that dephase nearby water protons. Clinically, iron oxide agents are used for liver lesion detection, where SPIO uptake by Kupffer cells darkens healthy tissue to highlight focal lesions. They also enable lymph node imaging by targeting macrophages, aiding in metastasis assessment. Ferumoxytol has been used off-label for MRI since the 2010s, particularly for vascular enhancement due to its blood-pool retention and safety in renal impairment, and received FDA approval in October 2025 as Ferabright for brain MRI in oncology patients. The first SPIO agent, ferumoxides, received FDA approval in 1996 for intravenous use in detecting liver lesions in patients with known or suspected tumors. Following discontinuations of several formulations like Resovist around 2009-2012 due to market factors, ferumoxytol has experienced resurgence post-2020 as a gadolinium alternative, further bolstered by its 2025 FDA approval for MRI contrast use.

Iron-Platinum and Hybrid Agents

Iron-platinum (FePt) nanoparticles represent an advanced class of superparamagnetic alloys designed to overcome limitations of traditional iron oxide agents, offering enhanced magnetic properties for MRI contrast enhancement. These nanoparticles typically feature a face-centered tetragonal structure, enabling superparamagnetism at sizes of 2-8 nm, which allows for tunable magnetism while minimizing remanent magnetization. Unlike pure iron oxides, FePt alloys exhibit significantly higher magnetic saturation values, up to approximately 1140 emu/cm³ in bulk form, providing superior T2 relaxivity for darker contrast in MRI images. Hybrid agents incorporating FePt or iron oxide with other materials further improve biocompatibility and functionality. For instance, silica-coated FePt nanoparticles enhance colloidal stability and reduce toxicity, with core-shell designs achieving high saturation magnetization while enabling surface functionalization for targeted delivery. Iron oxide-gold hybrids combine magnetic properties for T2 MRI contrast with gold's utility in computed tomography (CT), facilitating multimodal imaging; these structures, often 10-50 nm in size, demonstrate improved cellular uptake and reduced aggregation in biological environments. Alloying with platinum also confers chemical stability against oxidation, a key advancement in research from the 2010s onward. In applications, FePt and hybrid agents excel in theranostics, particularly for cancer imaging and treatment. They enable precise MRI tracking of targeted drug delivery systems, where the high relaxivity (often exceeding that of superparamagnetic iron oxides) highlights tumor locations via T2-weighted dark-field changes. Preclinical studies have demonstrated their efficacy in hepatocellular carcinoma visualization and magnetic fluid hyperthermia, with iron oxide-gold hybrids showing promise as nano-heaters for combined imaging and thermal therapy. As of 2025, these agents remain in preclinical development, with ongoing investigations into FDA investigational pathways for clinical translation, focusing on long-term biocompatibility and scalability.

Manganese-Based Agents

Properties and Traditional Uses

Manganese-based MRI contrast agents primarily utilize the Mn²⁺ ion as the paramagnetic center, which features five unpaired electrons, enabling efficient shortening of the longitudinal relaxation time (T1) of nearby water protons through dipole-dipole interactions. Common chelates include Mn-DTPA (manganese diethylenetriaminepentaacetate), designed to stabilize the Mn²⁺ ion and prevent free ion release, which could lead to toxicity. These agents exhibit T1 relaxivities (r1) typically in the range of 4-7 mM⁻¹s⁻¹ at clinical field strengths (e.g., 1.5-3 T), lower than some gadolinium-based agents but sufficient for contrast enhancement when dosed appropriately. Pharmacokinetically, manganese-based agents demonstrate rapid renal clearance following intravenous administration, with plasma half-lives on the order of minutes to hours, owing to the small size of the chelates. Their low inherent toxicity stems from manganese's role as an essential endogenous trace element, involved in enzymatic processes, which allows for safer excretion compared to non-physiological metals. Oral formulations, such as manganese chloride solutions, have been employed for gastrointestinal imaging, where they provide positive contrast in the bowel lumen without systemic absorption in significant amounts. Traditional applications of manganese-based agents emerged in the early 1980s, shortly after the inception of MRI technology, with initial experimental use of MnCl₂ and early chelates like Mn-DTPA for enhancing brain tumor visualization and cardiac perfusion imaging. In 1982, intravenous Mn chelates were demonstrated to differentiate ischemic myocardium in animal models, highlighting their potential for cardiovascular MRI. However, adoption remained limited due to the agents' lower relaxivity and concerns over potential Mn accumulation, leading to a preference for gadolinium-based alternatives by the late 1980s. Key advantages include the absence of nephrotoxicity, making them suitable for patients with renal impairment, unlike certain gadolinium agents. Additionally, the reversible Mn³⁺/Mn²⁺ redox couple offers potential for redox-sensitive imaging, where oxidation state changes could enable responsive contrast in hypoxic or oxidative environments, though this was underexplored in early applications.

Emerging Macrocyclic Agents

Emerging macrocyclic manganese-based contrast agents represent a significant advancement in MRI imaging, offering stable alternatives to gadolinium agents by leveraging manganese's biocompatibility while overcoming its historical instability through rigid cyclic chelation structures. These agents typically feature macrocyclic ligands, such as derivatives of 1,4,7,10-tetraazacyclododecane or triazacyclononane, that tightly bind Mn²⁺ ions, minimizing free ion release and associated toxicity risks. A key development is GE HealthCare's investigational macrocyclic manganese-based agent, which completed Phase I clinical trials in 2024, showing excellent tolerability in healthy volunteers with no serious adverse events, dose-limiting toxicities, or clinically significant changes in vital signs or laboratory parameters. This extra-cellular agent exhibits relaxivity comparable to macrocyclic gadolinium-based contrasts, enabling effective signal enhancement for general-purpose imaging. For specialized applications, macrocyclic designs have been tailored for hepatobiliary imaging, such as the Mn-NOTA-NP complex, where a 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) ligand conjugated with indocyanine green provides high stability and liver-specific uptake via organic anion-transporting polypeptides, akin to Gd-EOB-DTPA. This agent demonstrates an r₁ relaxivity of 9.01 mM⁻¹ s⁻¹ in human serum albumin at 3 T, surpassing many traditional Mn chelates and supporting reduced dosing for abdominal MRI while maintaining kinetic stability to prevent dissociation. Clinical evaluation of these macrocyclic agents is progressing, with GE HealthCare's compound having completed Phase I trials in 2024 and further clinical development ongoing as of 2025. Another investigational manganese-based agent, RVP-001 from Reveal Pharmaceuticals, entered Phase 2 trials in 2024 to assess safety and efficacy in patients with gadolinium-enhancing central nervous system lesions. Concurrent research from 2023 to 2025 has explored Mn nanoparticles to further boost relaxivity, exemplified by ultra-small MnO₂ nanoparticles coated with polyacrylic acid, achieving an r₁ of 29.0 mM⁻¹ s⁻¹ at 1.5 T and a low r₂/r₁ ratio of 1.8 for superior T₁-weighted contrast at low concentrations. These nanoparticle enhancements complement macrocyclic efforts by improving signal intensity and biocompatibility in preclinical models.

Alternative and Specialized Agents

Oral Agents

Oral MRI contrast agents are ingestible formulations designed to enhance visualization of the gastrointestinal tract by opacifying the bowel lumen, thereby improving differentiation of bowel from adjacent structures in abdominal and pelvic imaging. These agents are typically administered in volumes of 500-1000 mL to achieve adequate distension and uniform distribution throughout the small and large bowel. Key examples include ferric ammonium citrate (FAC), a paramagnetic positive contrast agent that shortens T1 relaxation times to produce a bright signal in the bowel lumen without significant systemic absorption. Another is ferumoxsil (Gastromark), a silicone-coated superparamagnetic iron oxide suspension classified as a non-absorbable ferrite, which primarily shortens T2 relaxation times for negative contrast, rendering the bowel dark against brighter surrounding tissues. Manganese chloride solutions have also been investigated as oral agents, offering T1 enhancement through partial absorption and hepatic uptake, though their use remains more experimental for gastrointestinal applications. These agents facilitate imaging of bowel diseases such as and tumors by reducing motion and susceptibility artifacts that can obscure pathology in pelvic and abdominal scans. Approved in the 1990s, such as Gastromark in 1996, they addressed early limitations in MRI bowel visualization but achieved limited market adoption due to variable efficacy in uniform opacification and patient tolerability issues. Despite their utility, oral agents like FAC and ferumoxsil often present drawbacks including unpleasant taste leading to poor compliance, gastrointestinal side effects such as nausea, and inconsistent bowel coating, contributing to their decline in routine clinical use as advanced MRI sequences have improved artifact suppression.

Protein-Based Agents

Protein-based MRI contrast agents represent a class of bioengineered conjugates that leverage the inherent specificity and biocompatibility of proteins to enhance targeted imaging in magnetic resonance imaging (MRI). These agents typically involve the attachment of paramagnetic metal ions, such as gadolinium () or manganese (), to protein scaffolds like albumin, transferrin, or antibodies, enabling prolonged circulation and receptor-mediated accumulation at sites of interest. Unlike small-molecule contrast agents, protein conjugates in the 50-100 kDa range, such as Gd-labeled human serum albumin (approximately 66 kDa), exhibit blood pool effects by remaining primarily in the vasculature, providing sustained contrast enhancement for vascular and extravascular imaging. The design of these agents emphasizes site-specific labeling to preserve the native protein's function while incorporating multiple metal-binding sites to amplify relaxivity. For instance, Gd chelates like DOTA are covalently linked to lysine residues on albumin or transferrin via activated esters, ensuring thermodynamic stability and minimal dissociation in vivo; this approach boosts longitudinal relaxivity (r1) by factors of 2-5 compared to unbound Gd complexes due to slower tumbling rates and increased water access. Similarly, antibodies can be conjugated with multiple Gd ions (up to 10-20 per molecule) at non-interfering sites, maintaining antigen-binding affinity for targeted delivery. Mn-based variants, such as those engineered into metalloprotein scaffolds, offer an alternative with potentially lower toxicity, achieving r1 values up to 20 mM⁻¹ s⁻¹ through optimized coordination environments. Applications of protein-based agents focus on molecular targeting, particularly for oncology and inflammatory conditions. Gd- or Mn-conjugated transferrin exploits the transferrin receptor's overexpression on tumor cells, facilitating receptor-mediated endocytosis and enhanced tumor contrast in preclinical models of breast and brain cancers. Antibody conjugates, such as those targeting on breast tumors or HLA-DR on immune cells, enable specific visualization of receptor-positive lesions, with signal enhancements up to 50% over background in mouse xenografts. For inflammation imaging, albumin-Gd conjugates accumulate in sites of vascular permeability, aiding detection of early atherosclerotic plaques or arthritic joints. These agents remain largely preclinical, with albumin-Gd constructs showing promise for vascular imaging in studies demonstrating safety and prolonged half-life (up to 4-6 hours). As of 2024, advanced protein-based agents like single-point mutated lanmodulin have shown high relaxivity and biocompatibility in preclinical studies, with potential for future clinical translation. Key advantages include extended circulation times (e.g., 2-10 hours versus minutes for small molecules) due to their size and protein nature, which reduces renal clearance and non-specific tissue uptake while promoting active targeting via receptor binding. This results in higher lesion-to-background ratios and lower required doses, minimizing potential toxicity risks associated with free Gd. Compared to traditional blood pool gadolinium agents, protein conjugates offer superior specificity without compromising relaxivity.

Nanoparticle-Based Agents

Nanoparticle-based MRI contrast agents represent an innovative class of materials that incorporate lanthanide ions such as gadolinium (Gd) or europium (Eu) into inorganic matrices like silica or gold, enabling enhanced imaging capabilities beyond traditional chelates. These agents typically range in size from 10 to 100 nm, allowing for favorable biodistribution and prolonged circulation while minimizing rapid renal clearance. For instance, Gd-doped mesoporous silica nanoparticles have demonstrated superior T1 contrast enhancement due to their porous structure, which facilitates water proton access to paramagnetic centers. Similarly, Eu-doped silica nanoparticles grafted with lanthanide complexes support bimodal MRI-optical imaging, leveraging Eu³⁺ for luminescence and Gd³⁺ for magnetic relaxation. Gold-based variants, such as Gd-loaded gold nanoparticles, combine the biocompatibility of gold with high Gd loading for amplified signal intensity in T1-weighted scans. Upconversion nanoparticles (UCNPs), often lanthanide-doped nanocrystals like NaYF₄:Yb/Er, enable multimodal MRI/optical imaging by converting near-infrared excitation to visible emission, penetrating deeper tissues with reduced autofluorescence. A key advantage of these nanoparticles is their ability to achieve a high payload of paramagnetic metals, often exceeding that of small-molecule chelates by incorporating thousands of Gd ions per particle, which boosts local relaxivity without increasing systemic exposure. This design mitigates Gd retention concerns associated with linear chelates by promoting more stable incorporation and efficient clearance pathways. Surface functionalization further enhances specificity, such as conjugation with folate ligands to target folate receptor-overexpressing cancer cells, improving tumor accumulation and reducing off-target effects. Recent developments from 2023 to 2025 have focused on biocompatible lanthanide with exceptionally high longitudinal relaxivity (r₁ > 20 mM⁻¹ s⁻¹), exemplified by spherical Gd₃₂ exhibiting r₁ = 265.87 mM⁻¹ s⁻¹ at 1 T, attributed to their aggregated that optimizes coordination. These advances emphasize surface modifications like for improved biocompatibility and reduced immunogenicity, paving the way for theranostic applications in preclinical models. Although clinical translation remains in early stages, platforms are progressing toward Phase I trials for combined and , particularly in . In applications, these agents excel in deep tissue imaging, where multimodal capabilities—such as MRI combined with optical or CT—provide comprehensive anatomical and functional insights into tumors. Stimulus-responsive designs, responsive to or enzymes in the , enable controlled release of contrast or therapeutic payloads, enhancing signal amplification at disease sites. By addressing Gd retention through high-payload encapsulation and targeted delivery, these nanoparticles offer a safer alternative for repeated imaging in patients with renal impairment.

Administration and Safety

Routes of Administration

The primary route of administration for most MRI contrast agents, including gadolinium-based agents (GBCAs), is intravenous (IV), typically via bolus injection to achieve rapid distribution and enhancement during imaging. For GBCAs such as gadobutrol or gadoterate, a standard dose of approximately 0.1 mmol/kg is administered as a rapid IV bolus at rates of 1-2 mL/second through a peripheral vein, often using a power injector for consistency. In contrast, certain superparamagnetic iron oxide (SPIO) agents like ferumoxytol require slower IV infusion to minimize side effects; these are administered at a dose of 1-3 mg Fe/kg over at least 15 minutes. For patients with renal impairment (e.g., eGFR <30 mL/min/1.73 m²), hydration protocols are employed prior to IV administration, such as 0.9% normal saline at 100 mL/hour for 6-12 hours before the procedure, to support renal function during contrast delivery. Oral administration can be used for gastrointestinal (GI) contrast to delineate bowel structures, though pharmaceutical iron oxide-based formulations are no longer commonly available. Non-medicinal options, such as diluted or solutions, are sometimes employed to provide negative contrast. Patients are typically instructed to fast for 4-6 hours beforehand, with occurring 30-60 minutes prior to scanning to optimize bowel opacification. Preparation involves ensuring homogeneity of the solution, and clear liquid intake may be permitted post- to avoid interference while awaiting . Less common routes include intra-articular injection for MR arthrography, where dilute contrast (e.g., 10-20 mL of solution mixed with saline) is directly injected into the space under fluoroscopic or guidance to enhance synovial visualization. is rare and generally not approved for standard GBCAs due to potential complications, though investigational uses have explored it for spinal . Emerging targeted delivery methods involve catheter-based under real-time MRI guidance, allowing localized agent deposition in specific vascular or tissue sites during interventional procedures. General protocols for all routes begin with patient screening, including history of allergies to contrast agents and assessment of renal function via serum creatinine or eGFR measurement, particularly for IV use. Post-administration monitoring involves observation for 15-30 minutes in a controlled setting to ensure procedural completion, with vital signs checked as needed. Agent-specific pharmacokinetics, such as rapid renal clearance for extracellular GBCAs versus reticuloendothelial uptake for SPIOs, guide the choice between bolus and infusion to align with imaging timing.

Safety Profiles and Risks

MRI contrast agents, particularly gadolinium-based contrast agents (GBCAs), carry specific safety concerns primarily related to (NSF) in patients with renal impairment. NSF is a rare but serious fibrosing condition associated with certain linear GBCAs in patients with severe (CKD stage 4 or 5, eGFR <30 mL/min/1.73 m²), though the incidence with macrocyclic group II agents is extremely low, estimated at less than 0.07% based on large cohort studies. No cases of NSF have been reported in dialysis patients receiving a single dose of macrocyclic GBCAs in monitored samples exceeding 200 patients. Gadolinium deposition in the and other tissues has been confirmed through postmortem and studies from 2014 to 2025, with higher retention observed after repeated administrations of linear GBCAs compared to macrocyclics; however, no clinical harm or neurological deficits have been directly attributed to this deposition across extensive reviews and human data. For superparamagnetic (SPIO) agents, reactions represent a key risk, with serious events reported in up to 0.7% of administrations for agents like ferumoxytol, often manifesting as ; remains rare and is typically limited to patients with underlying iron metabolism disorders or repeated high-dose exposures. Manganese-based agents pose risks of at high doses, potentially leading to —a Parkinson-like —due to free Mn²⁺ accumulation in the , though chelated formulations mitigate this when used within approved limits. Use of GBCAs in special populations requires caution. In pregnancy, GBCAs are classified as FDA C, and administration is generally avoided unless the benefits outweigh potential risks, due to limited data on fetal effects. For breastfeeding patients, interruption of nursing for 24-48 hours after GBCA administration is recommended to minimize infant exposure. Similar precautions apply to other contrast agents, with pediatric dosing adjusted based on weight and renal function. Regulatory guidelines emphasize risk mitigation through estimated (eGFR) screening prior to GBCA administration, with the FDA issuing class warnings in 2017 requiring updated labeling for all GBCAs to address NSF and tissue retention risks, recommending avoidance in patients with eGFR <30 mL/min/1.73 m² unless benefits outweigh potential harms. Alternatives such as non-contrast MRI protocols or are preferred in high-risk renal patients to avoid contrast entirely. As of 2025, data on newer macrocyclic agents like gadopiclenol indicate a favorable safety profile, with rates comparable to established GBCAs and lower dosing reducing retention concerns; global registries report overall reaction incidences for MRI contrasts at 0.06–0.17%, predominantly mild and self-limiting.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK482487/
  2. https://pubmed.ncbi.nlm.nih.gov/23090917/
  3. https://ajronline.org/doi/10.2214/AJR.23.30036
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4735235/
  5. https://link.springer.com/article/10.1007/s00330-024-11214-4
  6. https://radiopaedia.org/articles/mri-physics?lang=us
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4537356/
  8. https://radiologykey.com/contrast-agents-and-relaxation-effects/
  9. https://pubs.acs.org/doi/10.1021/acsomega.2c03549
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2949106/
  11. https://inis.iaea.org/collection/NCLCollectionStore/_Public/23/086/23086692.pdf
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2822463/
  13. https://radiologykey.com/intravascular-contrast-media-for-radiography-ct-mri-and-ultrasound/
  14. https://www.sciencedirect.com/science/article/abs/pii/S0360301604031402
  15. https://www.researchgate.net/publication/11664964_Conception_of_the_First_Magnetic_Resonance_Imaging_Contrast_Agents_A_Brief_History
  16. https://onlinelibrary.wiley.com/doi/full/10.1002/jmri.29181
  17. https://www.researchgate.net/publication/226328464_Relaxivity_of_MRI_Contrast_Agents
  18. http://www.mr-tip.com/serv1.php?type=db1&dbs=relaxivity
  19. https://pubmed.ncbi.nlm.nih.gov/24375901/
  20. https://onlinelibrary.wiley.com/doi/abs/10.1002/cmmi.1565
  21. https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2018.00158/full
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3024144/
  23. https://digital.library.unt.edu/ark:/67531/metadc897512/m2/1/high_res_d/942144.pdf
  24. https://www.osti.gov/servlets/purl/981516
  25. https://mriquestions.com/paramagnetic-relaxation.html
  26. https://pubs.acs.org/doi/abs/10.1021/jp9704067
  27. https://www.researchgate.net/figure/Schematic-representation-of-the-inner-sphere-relaxation-mechanism_fig1_5225121
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6392011/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3496483/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3741608/
  31. https://www.stelar.it/wp-content/uploads/2023/05/Stelar-application-note_MRI-contrast-agents.pdf
  32. https://www.researchgate.net/publication/327554163_Characterisation_of_magnetic_resonance_imaging_MRI_contrast_agents_using_NMR_relaxometry
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC2713805/
  34. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0149260
  35. https://www.sciencedirect.com/science/article/abs/pii/S109078070300435X
  36. https://mriquestions.com/uploads/3/4/5/7/34572113/rohrer_relaxivity_00004424-200511000-00005.pdf
  37. https://appliedradiology.com/articles/contrast-enhanced-mri-history-and-current-recommendations
  38. https://insightsimaging.springeropen.com/articles/10.1186/s13244-024-01626-7
  39. https://mriquestions.com/so-many-gd-agents.html
  40. https://www.sciencedirect.com/science/article/abs/pii/S0720048X08000478
  41. https://radiology.wisc.edu/wp-content/uploads/2017/10/gadolinium-based-contrast-dosing-charts.pdf
  42. https://www.ajnr.org/content/35/12/2215
  43. https://pubs.rsna.org/doi/full/10.1148/radiol.231454
  44. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC5220192/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC2464762/
  47. https://www.mdpi.com/2079-9721/10/4/122
  48. https://link.springer.com/article/10.1007/s00330-017-4902-0
  49. https://ajronline.org/doi/10.2214/AJR.12.8991
  50. https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-015-0176-0
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC3893895/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3281562/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC3170825/
  54. https://ajronline.org/doi/10.2214/AJR.19.22239
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC7593310/
  56. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022090s000TOC.cfm
  57. https://insightsimaging.springeropen.com/articles/10.1186/s13244-020-00928-w
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC4341386/
  59. https://radiopaedia.org/articles/gadobenate-dimeglumine?lang=us
  60. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021357s014%2C021358s013lbl.pdf
  61. https://pubs.rsna.org/doi/abs/10.1148/rg.296095515
  62. https://www.bracco.com/article/fda-approves-gadopiclenol-injection-us-market
  63. https://braccomr.com/clinical-data/
  64. https://journals.lww.com/investigativeradiology/fulltext/2022/10000/preclinical_profile_of_gadoquatrane__a_novel.1.aspx
  65. https://www.bayer.com/media/en-us/positive-results-from-phase-iii-study-for-bayers-investigational-contrast-agent-gadoquatrane/
  66. https://www.bayer.com/en/us/news-stories/gadoquatrane
  67. https://www.prnewswire.com/news-releases/bracco-announces-fda-approval-of-gadopiclenol-injection-a-new-macrocyclic-high-relaxivity-gadolinium-based-contrast-agent-which-will-be-commercialized-as-vueway-gadopiclenol-injection-and-vueway-gadopiclenol-pharmacy-bulk-p-301630124.html
  68. https://www.bracco.com/article/efficacy-and-safety-gadopiclenol
  69. https://www.rsna.org/news/2023/january/2022-chynn-award
  70. https://clinicaltrials.gov/study/NCT06846853
  71. https://journals.lww.com/investigativeradiology/fulltext/2025/06000/safety_of_gadopiclenol_after_its_first_year_of.8.aspx
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC9242635/
  73. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-identifies-no-harmful-effects-date-brain-retention-gadolinium
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC4679775/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC8692919/
  76. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/219868Orig1s000ltr.pdf
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC8021129/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC5337187/
  79. https://pubs.rsc.org/en/content/articlehtml/2014/ra/c3ra44319a
  80. https://www.sciencedirect.com/science/article/abs/pii/S0304885308000322
  81. https://pubs.acs.org/doi/abs/10.1021/acs.langmuir.9b00337
  82. https://onlinelibrary.wiley.com/doi/10.1155/2012/631584
  83. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/1477-3155-10-27
  84. https://iopscience.iop.org/article/10.1088/0957-4484/22/15/155101
  85. https://pubs.rsc.org/en/content/articlehtml/2022/na/d1na00613d
  86. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-021-01052-7
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC2962530/
  88. https://www.mdpi.com/1420-3049/28/21/7275
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC3203535/
  90. https://pubmed.ncbi.nlm.nih.gov/10398973/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC11066259/
  92. https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-announces-phase-i-results-first-its-kind
  93. https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-announces-phase-i-results-for-a-first-of-its-kind-macrocyclic-manganese-based-mri-contrast-agent
  94. https://pubmed.ncbi.nlm.nih.gov/37111359/
  95. https://www.clinicaltrialsarena.com/news/ge-healthcares-manganese-based-mri-contrast-agent-shines-in-phase-i-trial/
  96. https://clinicaltrials.gov/study/NCT06322342
  97. https://pubs.rsc.org/en/content/articlelanding/2023/bm/d3bm00443k
  98. https://www.sciencedirect.com/science/article/pii/S1742706125003848
  99. https://www.drugs.com/pro/gastromark.html
  100. https://pubmed.ncbi.nlm.nih.gov/7968284/
  101. https://pubmed.ncbi.nlm.nih.gov/11050639/
  102. https://pubmed.ncbi.nlm.nih.gov/22447731/
  103. https://ajronline.org/doi/pdf/10.2214/ajr.156.2.1898795
  104. https://www.fiercepharma.com/supply-chain/amag-closing-plant-moving-to-contract-manufacturing
  105. https://mriquestions.com/bowel-contrast-agents.html
  106. https://www.sciencedirect.com/topics/medicine-and-dentistry/ferumoxsil
  107. https://doi.org/10.1097/RLI.0000000000001057
  108. https://doi.org/10.1016/j.febslet.2013.01.044
  109. https://www.nature.com/articles/s41467-024-54167-4
  110. https://www.mdpi.com/2079-4991/15/14/1074
  111. https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2022.837032/full
  112. https://www.researchgate.net/publication/228092817_Silica_Nanoparticles_for_Bimodal_MRI-Optical_Imaging_by_Grafting_Gd3and_Eu3Tb3Complexes
  113. https://www.nature.com/articles/srep34367
  114. https://cancerimagingjournal.biomedcentral.com/articles/10.1186/s40644-024-00762-z
  115. https://www.researchgate.net/publication/269170583_Multi-Modal_Imaging_And_Cancer_Therapy_Using_Lanthanide_Oxide_Nanoparticles_Current_Status_And_Perspectives
  116. https://onlinelibrary.wiley.com/doi/10.1002/gch2.202400269
  117. https://research.tudelft.nl/files/233032667/1-s2.0-S2352952024000276-main.pdf
  118. https://academic.oup.com/nsr/article/10/4/nwad036/7043483
  119. https://www.sciencedirect.com/science/article/pii/S2352952024000276
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC12404209/
  121. https://pubs.rsc.org/en/content/articlehtml/2025/na/d5na00596e
  122. https://www.sciencedirect.com/science/article/abs/pii/S0010854524007483
  123. https://www.radiology.wisc.edu/wp-content/uploads/2017/10/UW-ferumoxytol-guidelines.pdf
  124. https://radiology.wisc.edu/documents/hydration-protocol/
  125. https://www.sciencedirect.com/science/article/pii/S1078817425000033
  126. https://www.nature.com/articles/s41598-025-03438-1
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC5553275/
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC6516866/
  129. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2757311
  130. https://pubmed.ncbi.nlm.nih.gov/24169070/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC12454587/
  132. https://www.sciencedirect.com/science/article/abs/pii/S1474442217301588
  133. https://link.springer.com/article/10.1007/s00330-023-10281-3
  134. https://www.acc.org/Latest-in-Cardiology/Articles/2025/07/28/17/07/Contrast-Media-in-Advanced-Cardiovascular-Imaging
  135. https://www.feraheme.com/wp-content/uploads/2020/07/Radiologist-Letter.pdf
  136. https://pubmed.ncbi.nlm.nih.gov/28092939/
  137. https://www.mdpi.com/2039-7283/15/8/137
  138. https://wires.onlinelibrary.wiley.com/doi/10.1002/wnan.116
  139. https://www.ajnr.org/content/early/2019/08/01/ajnr.A6152
  140. https://www.acr.org/Clinical-Resources/Contrast-Manual
  141. https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-warns-gadolinium-based-contrast-agents-gbcas-are-retained-body-requires
  142. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-warnings-using-gadolinium-based-contrast-agents-patients-kidney
  143. https://rayusradiology.com/wp-content/uploads/2019/02/CDI-contrast-guidelines-12_17_2017-Final-eae.pdf
  144. https://pubmed.ncbi.nlm.nih.gov/39692431/
  145. https://link.springer.com/article/10.1007/s00330-025-11675-1
Add your contribution
Related Hubs
User Avatar
No comments yet.